<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1665-1146</journal-id>
<journal-title><![CDATA[Boletín médico del Hospital Infantil de México]]></journal-title>
<abbrev-journal-title><![CDATA[Bol. Med. Hosp. Infant. Mex.]]></abbrev-journal-title>
<issn>1665-1146</issn>
<publisher>
<publisher-name><![CDATA[Instituto Nacional de Salud, Hospital Infantil de México Federico Gómez]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1665-11462025000200003</article-id>
<article-id pub-id-type="doi">10.24875/bmhim.24000080</article-id>
<title-group>
<article-title xml:lang="en"><![CDATA[Hodgkin and non-Hodgkin lymphomas in pediatric-age patients of Northeast Mexico: 18-year outcomes and survival rates at an academic center]]></article-title>
<article-title xml:lang="es"><![CDATA[Linfomas Hodgkin y no Hodgkin en pacientes en edad pediátrica del noreste de México: resultados y tasas de supervivencia a 18 años en un centro académico]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jaime-Pérez]]></surname>
<given-names><![CDATA[José C.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Beltrán-López]]></surname>
<given-names><![CDATA[Ana L.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Jiménez-Antolínez]]></surname>
<given-names><![CDATA[Valentina]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Barragán-Longoria]]></surname>
<given-names><![CDATA[Renata]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Colunga-Pedraza]]></surname>
<given-names><![CDATA[Julia E.]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[González-Llano]]></surname>
<given-names><![CDATA[Óscar]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez-Almaguer]]></surname>
<given-names><![CDATA[David]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad Autónoma de Nuevo León Dr. José Eleuterio González University Hospital, School of Medicine Department of Hematology]]></institution>
<addr-line><![CDATA[Monterrey ]]></addr-line>
<country>Mexico</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>04</month>
<year>2025</year>
</pub-date>
<volume>82</volume>
<numero>2</numero>
<fpage>107</fpage>
<lpage>114</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S1665-11462025000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S1665-11462025000200003&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S1665-11462025000200003&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Background: Hodgkin lymphoma (HL) and non-HL (NHL) are the third and fourth most common malignancies during childhood, with limited information available from Latin America.  Method: We retrospectively studied patients with HL and NHL from a single academic center in Northeast Mexico between 2002 and 2020. Data included treatment regimens, staging, and survival outcomes. Survival was determined by Kaplan–Meier analysis, and features of lymphomas were compared using the X2 test.  Results: The study included 75 patients, 36 (48%) with HL and 39 (52%) with NHL. Males predominated (70%); the median age was 9 years. Stages III and IV were detected in 59% and median follow-up reached 50 months. Relapse occurred in 16 (21%) patients, 9 (12%) in the HL group and 7 (9%) in the NHL group. Thirteen (17.3%) patients underwent transplantation, 12 (85%) in the HL group; 11 are alive. Most deaths, 10/11 (91%), occurred in NHL patients. Five-year overall survival rates were 96% (95% confidence interval [CI] 95.6-97) for HL and 75% (95% CI 74.9-76.3) for NHL (p = 0.004). Five-year disease-free survival was 70% for HL (95% CI 69-72.5) and 69% (95% CI 67.7-71) for NHL (p = 0.672).  Conclusion: Pediatric-age HL and NHL had similar frequency in the study population; most patients presented with advanced disease at diagnosis. A high success rate was documented for HL, while NHL outcomes were suboptimal.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  Introducción: Los linfomas Hodgkin (LH) y no Hodgkin (LNH) son la tercera y cuarta neoplasia maligna durante la infancia, con escasa información sobre sus características y evolución en Latinoamérica.  Método: Se incluyeron pacientes &#8804; 18 años con LH y LNH de un centro académico en el noreste de México entre 2002 y 2020. Los datos analizados incluyeron modalidades de tratamiento, estadificación y supervivencia. La supervivencia se determinó por análisis de Kaplan–Meier y las características de los linfomas se compararon mediante X2.  Resultados: Se incluyeron 75 pacientes, 36 (48%) con HL y 39 (52%) con LNH. Predominaron los varones (70%); la edad media fue de 9 años. Se detectaron estadios III y IV en el 59%, la mediana de seguimiento alcanzó los 50 meses. La recaída se produjo en 16 (21%) pacientes, 9 (12%) HL y 7 (9%) LNH. Trece (17.3%) pacientes fueron sometidos a trasplante, 12 (85%) en el grupo HL, 11 vivos actualmente. La mayoría de las muertes, 10/11 (91%), ocurrieron en pacientes con LNH. La sobrevida general (SG) a cinco años fue 96 % para LH y 75 % para LNH, (p = 0,004). La sobrevida libre de eventos (SLE) fue del 70 % para HL (IC del 95 %: 69-72,5) y del 69 % (IC del 95 %: 67,7-71) para LNH (p = 0,672).  Conclusión: Los LH y LNH en edad pediátrica tuvieron una frecuencia similar en la población del estudio. Se documentó una alta tasa de curación para LH, mientras que para LNH los resultados fueron subóptimos.]]></p></abstract>
<kwd-group>
<kwd lng="en"><![CDATA[Pediatric lymphomas]]></kwd>
<kwd lng="en"><![CDATA[Non-Hodgkin lymphoma]]></kwd>
<kwd lng="en"><![CDATA[Hodgkin lymphoma]]></kwd>
<kwd lng="en"><![CDATA[Transplantation in pediatric lymphomas]]></kwd>
<kwd lng="en"><![CDATA[Survival in pediatric lymphomas]]></kwd>
<kwd lng="es"><![CDATA[Linfomas pediátricos]]></kwd>
<kwd lng="es"><![CDATA[Linfoma de Hodgkin]]></kwd>
<kwd lng="es"><![CDATA[Linfoma no Hodgkin]]></kwd>
<kwd lng="es"><![CDATA[Trasplante en linfomas pediátricos]]></kwd>
<kwd lng="es"><![CDATA[Supervivencia en linfomas de la infancia]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Siegel]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Miller]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Wagle]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer statistics]]></article-title>
<source><![CDATA[CA Cancer J Clin]]></source>
<year>2023</year>
<volume>73</volume>
<page-range>17-48</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<article-title xml:lang=""><![CDATA[Surveillance, Epidemiology, and End Results Program. Cancer Stat Facts: Non-Hodgkin Lymphoma]]></article-title>
<source><![CDATA[U.S. National Institutes of Health, Natio-nal Cancer Institute]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Matasar]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Zelenetz]]></surname>
<given-names><![CDATA[AD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Overview of lymphoma diagnosis and management]]></article-title>
<source><![CDATA[Radiol Clin North Am]]></source>
<year>2008</year>
<volume>46</volume>
<page-range>175-98, vii</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Altekruse]]></surname>
<given-names><![CDATA[SF]]></given-names>
</name>
<name>
<surname><![CDATA[Adamson]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Seibel]]></surname>
<given-names><![CDATA[NL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Declining childhood and adolescent cancer mortality]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2014</year>
<volume>120</volume>
<page-range>2497-506</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bethke]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Varga]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Weinhage]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Sabharwal]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Mellgren]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Randau]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Patient parameters and response after administration of rituximab in pediatric mature B-cell non-Hodgkin lymphoma]]></article-title>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2022</year>
<volume>69</volume>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zucca]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Rohatiner]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Magrath]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Cavalli]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Epidemiology and management of lymphoma in low-income countries]]></article-title>
<source><![CDATA[Hematol Oncol]]></source>
<year>2011</year>
<volume>29</volume>
<page-range>1-4</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Belsky]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Hochberg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Giulino-Roth]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Diagnosis and management of Hodgkin lymphoma in children, adolescents, and young adults]]></article-title>
<source><![CDATA[Best Pract Res Clin Haematol]]></source>
<year>2023</year>
<volume>36</volume>
<page-range>101445</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chantada]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Lam]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
<name>
<surname><![CDATA[Howard]]></surname>
<given-names><![CDATA[SC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Optimizing outcomes for children with non-Hodgkin lymphoma in low- and middle-income countries by early correct diagnosis, reducing toxic death and preventing abandonment]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2019</year>
<volume>185</volume>
<page-range>1125-35</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Minard-Colin]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Brugières]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Reiter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Cairo]]></surname>
<given-names><![CDATA[MS]]></given-names>
</name>
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Woessmann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-hodgkin lymphoma in children and adolescents:progress through effective collaboration, current knowledge, and challenges ahead]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>2963-74</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gómez-Almaguer]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[González-Llano]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Jiménez-Antolinez]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez-De]]></surname>
<given-names><![CDATA[León A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of classical Hodgkin's lymphoma in children and adolescents]]></article-title>
<source><![CDATA[Expert Opin Pharmacother]]></source>
<year>2019</year>
<volume>20</volume>
<page-range>1227-34</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ghafoor]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prognostic factors in pediatric Hodgkin lymphoma:experience from a developing country]]></article-title>
<source><![CDATA[Leuk Lymphoma]]></source>
<year>2020</year>
<volume>61</volume>
<page-range>344-50</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abdullaev]]></surname>
<given-names><![CDATA[FI]]></given-names>
</name>
<name>
<surname><![CDATA[Rivera-Luna]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Roitenburd-Belacortu]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Espinosa-Aguirre]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pattern of childhood cancer mortality in Mexico]]></article-title>
<source><![CDATA[Arch Med Res]]></source>
<year>2000</year>
<volume>31</volume>
<page-range>526-31</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moleti]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Hadad]]></surname>
<given-names><![CDATA[SA]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Jadiry]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Darraji]]></surname>
<given-names><![CDATA[AF]]></given-names>
</name>
<name>
<surname><![CDATA[Al-Saeed]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[De Vellis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of children with B-cell non-Hodgkin lymphoma in a low-income country]]></article-title>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2011</year>
<volume>56</volume>
<page-range>560-7</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Peña-Hernandez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ortiz]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Garcia]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Fuentes-Alabi]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Martinez]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcome of pediatric non-Hodgkin lymphoma in Central America:a report of the Association of Pediatric Hematology Oncology of Central America (AHOPCA)]]></article-title>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2019</year>
<volume>66</volume>
</nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gross]]></surname>
<given-names><![CDATA[TG]]></given-names>
</name>
<name>
<surname><![CDATA[Biondi]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Paediatric non-Hodgkin lymphoma in low and middle income countries]]></article-title>
<source><![CDATA[Br J Haematol]]></source>
<year>2016</year>
<volume>173</volume>
<page-range>651-4</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gualco]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Klumb]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Barber]]></surname>
<given-names><![CDATA[GN]]></given-names>
</name>
<name>
<surname><![CDATA[Weiss]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Bacchi]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pediatric lymphomas in Brazil]]></article-title>
<source><![CDATA[Clinics (Sao Paulo)]]></source>
<year>2010</year>
<volume>65</volume>
<page-range>1267-78</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lones]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Raphael]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Perkins]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Wotherspoon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Terrier-Lacombe]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sposto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mature B-cell lymphoma in children and adolescents:international group pathologist consensus correlates with histology technical quality]]></article-title>
<source><![CDATA[J Pediatr Hematol Oncol]]></source>
<year>2006</year>
<volume>28</volume>
<page-range>568-74</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pedrosa]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
<name>
<surname><![CDATA[Pedrosa]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Lins]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Pontes-Neto]]></surname>
<given-names><![CDATA[NT]]></given-names>
</name>
<name>
<surname><![CDATA[Falbo]]></surname>
<given-names><![CDATA[GH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Non-Hodgkin's lymphoma in childhood:clinical and epidemiological characteristics and survival analysis at a single center in Northeast Brazil]]></article-title>
<source><![CDATA[J Pediatr (Rio J)]]></source>
<year>2007</year>
<volume>83</volume>
<page-range>547-54</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Castellanos]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Barrantes]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Báez]]></surname>
<given-names><![CDATA[LF]]></given-names>
</name>
<name>
<surname><![CDATA[Gamboa]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Peña]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Alabi]]></surname>
<given-names><![CDATA[Soad]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A chemotherapy only therapeutic approach to pediatric Hodgkin lymphoma: AHOPCA LH 1999]]></article-title>
<source><![CDATA[Pediatr Blood Cancer]]></source>
<year>2014</year>
<volume>61</volume>
<page-range>997-1002</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kourti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Papakonstantinou]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Papagianni]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Arsos]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Loannidou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pantoleon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Hodgkin lymphoma in children and adolescents of Northern Greece: 25-year results and long-term follow-up]]></article-title>
<source><![CDATA[J Pediatr Hematol Oncol]]></source>
<year>2023</year>
<volume>45</volume>
<page-range>322-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rodriguez-Galindo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Friedrich]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Alcasabas]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Antillon]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Banavali]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge]]></article-title>
<source><![CDATA[J Clin Oncol]]></source>
<year>2015</year>
<volume>33</volume>
<page-range>3065-73</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wyatt]]></surname>
<given-names><![CDATA[KD]]></given-names>
</name>
<name>
<surname><![CDATA[Birz]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Castellino]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Henderson]]></surname>
<given-names><![CDATA[TO]]></given-names>
</name>
<name>
<surname><![CDATA[Lucas Jr]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Pei]]></surname>
<given-names><![CDATA[Q]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Accelerating pediatric Hodgkin lymphoma research: the Hodgkin lymphoma data collaboration (NODAL)]]></article-title>
<source><![CDATA[J Natl Cancer Inst]]></source>
<year>2024</year>
<volume>116</volume>
<page-range>642-6</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Zheng]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Luo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kanf]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Niedermann]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Zhao]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Lifetime risks of second primary malignancies after pediatric Hodgkin lymphoma and non-Hodgkin lymphoma]]></article-title>
<source><![CDATA[J Cancer Res Clin Oncol]]></source>
<year>2024</year>
<volume>150</volume>
<page-range>41</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
